Contact
searchSearch
HMP Global

Biosimilars Topic Center

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network
News
Biosimilar Infliximab Appears Safe, Effective in IBD Patients
12/15/2017
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the...
12/15/2017
Pharmacy Learning Network
News
Pharmacist Role in Promoting Proper Biosimilar Usage
12/14/2017
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD,...
12/14/2017
Pharmacy Learning Network
News
FDA Approves Another Biosimilar for RA Drug
12/14/2017
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a...
12/14/2017
Pharmacy Learning Network
News
FDA Approves First Biosimilar for Breast, Stomach Cancer
12/01/2017
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a...
12/01/2017
Pharmacy Learning Network
News
The Challenges of Bringing Biosimilars to Market
11/21/2017
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a...
11/21/2017
Pharmacy Learning Network

Newsfeed

News
Communication Needed to Improve Biosimilar Transition, Adherence
10/19/2017
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid...
10/19/2017
Pharmacy Learning Network
News
FDA Approves Amgen`s Cheaper Copy of Arthritis Drug Humira
09/23/2016
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper,...
09/23/2016
Pharmacy Learning Network
News
Novartis Biosimilar Takes Aim at Amgen`s Enbrel
10/23/2015
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis...
10/23/2015
Pharmacy Learning Network
News
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
08/28/2015
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday...
08/28/2015
Pharmacy Learning Network
PharmLaw
Iowa Attorney General Accuses Insulin Makers and PBMs of Deceptive Pricing Practices
02/03/2026
Juliet Gallagher
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna Bird has filed a sweeping lawsuit against major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a coordinated, years-long scheme to artificially inflate the prices of insulin and other...
Iowa Attorney General Brenna...
02/03/2026
Pharmacy Learning Network
News
Antacid Tablets Recalled Due to Failed Disintegration Specifications
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug Administration (FDA) has issued a Class II recall for INON ACE Antacid Tablets due to failed disintegration specifications, which may reduce the product’s effectiveness in relieving indigestion and gas.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
News
Glycopyrrolate Oral Solution Recalled Due to Degradation Specification Failure
01/29/2026
Hannah Musick
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been issued for glycopyrrolate oral solution due to degradation/impurity specification failure.
A Class III recall has been...
01/29/2026
Pharmacy Learning Network
News
Icosapent Ethyl Capsules Under Class II Recall
01/29/2026
Hannah Musick
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug Administration (FDA) is monitoring a Class II recall of icosapent ethyl capsules after capsule leakage caused subpotency, potentially affecting cardiovascular risk reduction therapy in patients with elevated triglycerides.
The US Food and Drug...
01/29/2026
Pharmacy Learning Network
PharmLaw
PCMA Sues California Over SB 41, Challenging PBM Fiduciary Duties Under ERISA
01/27/2026
Juliet Gallagher
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious pharmacy benefit manager (PBM) reform effort has drawn an immediate legal challenge, as the Pharmaceutical Care Management Association (PCMA) filed a federal lawsuit contesting key provisions of Senate Bill 41 (SB...
California’s most ambitious...
01/27/2026
Pharmacy Learning Network
News
Recall Issued for Diclofenac Sodium Topical Gel Due to pH Specification Failure
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug Administration (FDA) is overseeing a nationwide, voluntary Class III recall of diclofenac sodium topical gel 1% after the product failed to meet pH specifications, affecting more than 92 000 tubes distributed across the...
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
News
Furosemide 40 mg Tablets Recalled Due to Foreign Substance Contamination
01/22/2026
Grace Taylor, MS, MA
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug Administration (FDA) is alerting pharmacists to a voluntary Class II nationwide recall of Furosemide 40 mg tablets after a foreign substance was detected in a distributed lot.
The US Food and Drug...
01/22/2026
Pharmacy Learning Network
PharmLaw
Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged GLP-1 Antitrust Violations
01/21/2026
Juliet Gallagher
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding pharmacy has filed an antitrust lawsuit accusing Eli Lilly and Novo Nordisk of unlawfully restricting competition in the market for GLP-1 medications, escalating a legal battle over compounded versions of...
An Arizona-based compounding...
01/21/2026
Pharmacy Learning Network
News
Imprimis NJOF Initiates Class II Recall of Tri-Moxi+ Intraocular Injection Due to Particulate Matter
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling Tri-Moxi+® (Triamcinolone 9 mg/0.6 mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, NDC 71384-746-06. The recall encompasses 314 boxes totaling 6280 pre-filled syringes. Affected product...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network
News
FDA Reports Class II Recall of Imprimis Intraocular Dexamethasone Injections Due to Glass Particulates
01/15/2026
Juliet Gallagher
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling two compounded intraocular injectable drug products distributed nationwide in the US. The first product, Dexamethasone Moxifloxacin Intraocular Injection (1 mg/mL and 5 mg/mL, 1 mL, Rx only; NDC 71384-512-0.1),...
Imprimis NJOF, LLC is recalling...
01/15/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use